MX347257B - Solido de gamma-carbolinas fusionadas con heterociclos substituidos. - Google Patents
Solido de gamma-carbolinas fusionadas con heterociclos substituidos.Info
- Publication number
- MX347257B MX347257B MX2014007104A MX2014007104A MX347257B MX 347257 B MX347257 B MX 347257B MX 2014007104 A MX2014007104 A MX 2014007104A MX 2014007104 A MX2014007104 A MX 2014007104A MX 347257 B MX347257 B MX 347257B
- Authority
- MX
- Mexico
- Prior art keywords
- carbolines
- substituted heterocycle
- solid
- heterocycle fused
- fused gamma
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3606908P | 2008-03-12 | 2008-03-12 | |
| PCT/US2009/001608 WO2009114181A2 (en) | 2008-03-12 | 2009-03-12 | Substituted heterocycle fused gamma-carbolines solid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX347257B true MX347257B (es) | 2017-04-20 |
Family
ID=41065729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007104A MX347257B (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8648077B2 (OSRAM) |
| EP (1) | EP2262505B1 (OSRAM) |
| JP (1) | JP5611846B2 (OSRAM) |
| KR (2) | KR20150140418A (OSRAM) |
| CN (2) | CN102046175B (OSRAM) |
| AU (1) | AU2009223701B2 (OSRAM) |
| CA (1) | CA2716730C (OSRAM) |
| DK (1) | DK2262505T3 (OSRAM) |
| ES (1) | ES2530090T3 (OSRAM) |
| HR (1) | HRP20141178T1 (OSRAM) |
| IL (3) | IL207772A0 (OSRAM) |
| MX (2) | MX347257B (OSRAM) |
| PL (1) | PL2262505T3 (OSRAM) |
| PT (1) | PT2262505E (OSRAM) |
| SI (1) | SI2262505T1 (OSRAM) |
| WO (1) | WO2009114181A2 (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102372149B1 (ko) | 2007-03-12 | 2022-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US9107696B2 (en) * | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| WO2013155504A1 (en) * | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| AU2015240526A1 (en) | 2014-04-04 | 2016-11-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX388258B (es) | 2014-04-04 | 2025-03-19 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| CN110402244B (zh) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Lsd1抑制剂的盐 |
| PT3407888T (pt) | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
| JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP2019513143A (ja) * | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| JP6997718B2 (ja) * | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| SI3497104T1 (sl) | 2016-08-09 | 2021-12-31 | Teva Pharmaceuticals International Gmbh | Trdne oblike soli lumateperon ditosilata |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN116327770B (zh) | 2017-03-24 | 2025-10-31 | 细胞内治疗公司 | 新组合物和方法 |
| CN110636845A (zh) | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
| BR112020001666A2 (pt) | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| WO2019102240A1 (en) * | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
| CN109867674A (zh) * | 2017-12-05 | 2019-06-11 | 上海度德医药科技有限公司 | 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型 |
| CA3094204A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3095101A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Deuterated octahydro-quinoxaline derivatives and pharmaceutical compositions thereof use in the treatment of diseases involving serotonin 5-ht2a, dopamine d1/d2 and/or serotonin reuptake transporter (sert) pathways |
| MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
| KR102888393B1 (ko) | 2018-06-06 | 2025-11-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 염 및 결정 |
| MX2020013335A (es) | 2018-06-08 | 2021-05-27 | Intra Cellular Therapies Inc | Metodos novedosos. |
| KR102778034B1 (ko) | 2018-06-11 | 2025-03-12 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| AU2019288476A1 (en) | 2018-06-21 | 2021-03-18 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| EP3843729A4 (en) | 2018-08-29 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW COMPOSITIONS AND METHODS |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
| BR112021004053A2 (pt) | 2018-09-07 | 2021-05-25 | Aquestive Therapeutics, Inc. | composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos |
| US20220024924A1 (en) | 2018-11-27 | 2022-01-27 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
| WO2020131895A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CA3121635A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Serotonin 5-ht2a receptor antagonist |
| MX2021007143A (es) | 2018-12-17 | 2021-08-18 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020182978A1 (en) | 2019-03-13 | 2020-09-17 | Sandoz Ag | Crystalline salt of a 5-ht2a receptor antagonist |
| JP7673040B2 (ja) | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| WO2021062307A1 (en) | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2020373100A1 (en) | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| CA3159389A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions comprising diazepam and methods of treatment |
| WO2021119334A1 (en) | 2019-12-11 | 2021-06-17 | Intra-Cellular Therapies, Inc. | Organic compound |
| JP7727634B2 (ja) | 2019-12-19 | 2025-08-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 統合失調症処置方法 |
| CA3208345A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| MX2023014398A (es) * | 2021-06-07 | 2023-12-15 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CA3252857A1 (en) | 2022-05-18 | 2023-11-23 | Intra-Cellular Therapies, Inc. | NEW PROCESSES |
| CA3274836A1 (en) | 2022-12-30 | 2024-07-04 | Intra-Cellular Therapies, Inc. | Fused heterocyclic gamma-carbolines acting on the 5-HT2A serotonin receptor |
| WO2024173901A1 (en) | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| AR024378A1 (es) | 1999-06-15 | 2002-10-02 | Du Pont Pharm Co | Gamma-carbolinas fusionadas heterociclicas sustituidas |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE602004017325D1 (de) | 2003-07-21 | 2008-12-04 | Smithkline Beecham Corp | (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon |
| KR102372149B1 (ko) | 2007-03-12 | 2022-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2009
- 2009-03-12 PL PL09718951T patent/PL2262505T3/pl unknown
- 2009-03-12 KR KR1020157034267A patent/KR20150140418A/ko not_active Withdrawn
- 2009-03-12 EP EP09718951.8A patent/EP2262505B1/en active Active
- 2009-03-12 DK DK09718951.8T patent/DK2262505T3/en active
- 2009-03-12 CN CN200980108387.XA patent/CN102046175B/zh active Active
- 2009-03-12 ES ES09718951.8T patent/ES2530090T3/es active Active
- 2009-03-12 HR HRP20141178AT patent/HRP20141178T1/hr unknown
- 2009-03-12 SI SI200931092T patent/SI2262505T1/sl unknown
- 2009-03-12 AU AU2009223701A patent/AU2009223701B2/en active Active
- 2009-03-12 PT PT97189518T patent/PT2262505E/pt unknown
- 2009-03-12 JP JP2010550697A patent/JP5611846B2/ja active Active
- 2009-03-12 WO PCT/US2009/001608 patent/WO2009114181A2/en not_active Ceased
- 2009-03-12 US US12/922,056 patent/US8648077B2/en active Active
- 2009-03-12 MX MX2014007104A patent/MX347257B/es unknown
- 2009-03-12 MX MX2010010024A patent/MX2010010024A/es active IP Right Grant
- 2009-03-12 CN CN201510456013.4A patent/CN105237536A/zh active Pending
- 2009-03-12 KR KR1020107022312A patent/KR101610977B1/ko active Active
- 2009-03-12 CA CA2716730A patent/CA2716730C/en active Active
-
2010
- 2010-08-24 IL IL207772A patent/IL207772A0/en unknown
-
2014
- 2014-02-11 US US14/177,689 patent/US9199995B2/en active Active
-
2015
- 2015-11-30 US US14/954,845 patent/US9586960B2/en not_active Ceased
-
2018
- 2018-11-28 IL IL263338A patent/IL263338A/en unknown
-
2019
- 2019-03-06 US US16/294,607 patent/USRE48825E1/en active Active
-
2022
- 2022-01-09 IL IL289706A patent/IL289706A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347257B (es) | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| MX349630B (es) | Alfa-amilasas. | |
| MX2020001497A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| ZA201204031B (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
| MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
| ZA201202613B (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| MY155330A (en) | Methods for salt production | |
| ZA201404327B (en) | Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof | |
| MX2011012623A (es) | Construcciones de casb7439. | |
| MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
| MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
| EA201001870A1 (ru) | Новые кристаллические формы рабепразола натрия | |
| WO2009062659A3 (en) | Polymorphs of enantiopure erdosteine | |
| EA201001353A1 (ru) | Гидробромид ивабрадина | |
| WO2012063115A3 (en) | Process for the preparation of rosuvastatin calcium via novel amine intermediate | |
| MX2010003056A (es) | Polimorfos de valomaciclovir. | |
| UA99198C2 (ru) | Соединения фенантренона, композиция, содержащая их, и способ лечения | |
| WO2008111018A3 (en) | Process for the preparation of crystals of prulifloxacin | |
| MY153904A (en) | Method of producing pharmacologically pure crystals |